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Tumor Immunoediting by NKp46
Moran Elboim,* Roi Gazit, † Chamutal Gur,* Hormas Ghadially,* Gili Betser-Cohen,* and Ofer Mandelboim* NK cells interact with a wide variety of hazardous cells including pathogen-infected and tumor cells. NKp46 is a specific NK killer receptor that recognizes various influenza hemagglutinins and unknown tumor ligands. It was recently shown that NKp46 plays a significant role in the in vivo eradication of tumor cells; however, the role played by NKp46 in vivo with regard to tumor development is still unclear. In this study, we used the 3-methylcholanthrene (MCA)-induced fibrosarcoma model in NKp46-deficient mice to test the NKp46 recognition of carcinogen-induced tumors. We show that although the rate of MCA-induced tumor formation was similar in the presence and in the absence of NKp46, the expression of its unknown ligands was NKp46 dependent. The unknown NKp46 ligands were nearly absent in tumors that originated in wild-type mice, whereas they were detected in tumors that originated in the NKp46-deficient mice. We demonstrate that the interactions between NKp46 and its MCA tumor-derived ligands lead to the secretion of IFN-g but not to the elimination of the MCA-derived tumor cells. In addition, we show that the in vivo growth of MCA-derived tumor cells expressing high levels of the NKp46 ligands is NKp46 and IFN-g dependent. Thus, we present in this study a novel NKp46-mediated mechanism of tumor editing. The Journal of Immunology, 2010, 184: 5637-5644.
N atural killer cells are innate lymphocytes able to quickly respond to a wide range of transformed and pathogeninfected cells (1) (2) (3) . The activity of NK cells is controlled by a balance of signals delivered by inhibitory and activating receptors (1, 4) . The main activating receptors include NKp46, NKp44, and NKp30 (collectively known as the natural cytotoxicity receptors [NCRs] ), NKp80, 2B4, and NKG2D (5, 6) . In mice, NKG2D and 2B4 are present; however, the only functional member of the NCRs is the mouse ortholog of the human NKp46, named NCR1 (5, 7) . Only a few ligands were identified for the activating NK receptors. These ligands are either tumor derived, such as B7-H6, an NKp30 ligand, stress induced, such as the ligands for NKG2D, or self-ligands, such as AICL for NKp80 and BAT3 for NKp30 (6, (8) (9) (10) (11) . With regard to the NCRs, we have demonstrated that the viral hemagglutinin (HA) proteins of various influenza strains interact with the human NKp44 and NKp46 and with the mouse NCR1 and that these interactions lead to increased killing of influenza-infected cells (7, 12, 13) . In addition, we showed that NKp30 interacts with the HCMV's pp65 protein, leading to the inhibition of killing by NK cells (14) .
Our group knocked out the Ncr1 gene and inserted the GFP reporter gene instead (7) . Almost all NK cells in the knockout (KO) and heterozygous mice are labeled green, and the function of the NCR1 receptor in the KO mice is impaired (7) . We have demonstrated that the NCR1 KO mice are sensitive to influenza infection, thus confirming in vivo the importance of the NKp46/NCR1-HA interactions. Although the function of NK cells against viral infections was studied in detail (1, 15, 16) , only limited number of studies investigated the in vivo function of NKp46 against tumors, mainly by using tumor cell lines (17, 18) . Thus, whether NKp46 is also important for the growth of carcinogen-induced tumors and what would be the effect of the NKp46 on tumor immunoediting was not investigated.
The immune response against developing tumors was studied in detail using the MCA model (19, 20) . Smyth and colleagues (20) define three stages of tumor immunoediting: elimination, equilibrium, and escape. They demonstrated that the major immune populations involved in tumor immunoediting are T cells. The involvement of NK cells in immunoediting has so far been studied only in relation to NKG2D and DNAM1 (19, 21, 22) . It was shown that the MCA-induced tumors were more frequently observed in mice treated with blocking anti-NKG2D Abs (22) . In contrast, another report failed to observe an increased incidence of MCAinduced sarcomas in NKG2D-deficient mice (19) . Moreover, because NKG2D is also expressed by several T cell subsets (10) , the effect of a specific NK cell receptor such as NKp46 on the development of carcinogen-induced tumors and on tumor immunoediting remains obscure. By using the MCA-induced carcinogenesis model in Ncr1-deficient mice, we demonstrate in this study a tumor immunoediting mechanism aimed at reducing the NCR1-dependent IFN-g secretion during tumor development.
Materials and Methods

Mice
All experiments were performed using 8-to 12-wk-old C57BL/6 mice. The generation of the Ncr1 gfp/gfp mice was described previously (7) . IFN-gdeficient mice (B6.129S7-Ifng
Generation of MCA-induced cell lines
Two weeks after tumor appearance, the tumors were removed, and part of the tumor was taken for digestion by trypsin for 5 min. Following this trypsin treatment, tumors were mashed in a culture dish, and RPMI 1640 medium was added. After an overnight incubation in 37˚C and 5% CO 2 , tumor clumps were removed, and the remaining cells were used as tumorderived cell lines that were grown in RPMI 1640 medium supplemented with 10% FCS and 1% sodium pyruvate, glutamine, nonessential amino acids, and penicillin-streptomycin solution.
Fusion proteins and flow cytometry
The NCR1-Ig, NKp46-Ig, and NKG2D-Ig fusion proteins were generated in COS-7 cells and purified by affinity chromatography using a protein G column, as described previously (13) . The staining of cell lines was visualized using a secondary PE-conjugated goat anti-human Abs (Jackson ImmunoResearch Laboratories, West Grove, PA).
BW reporter assay
A total of 50,000 BW or BW-NKp46-z cells were coincubated at 1:1 ratio with 50,000 irradiated (3000 rad) specified cells of various cell lines for 48 h at 37˚C and 5% CO 2 . Supernatants were collected and the levels of IL-2 were quantified by using commercially available anti-mouse IL-2 mAbs (BD Pharmingen, San Diego, CA) and standard ELISA.2332
Growth of MCA tumor cell lines
All experiments were performed by using 8-to 12-wk-old C57BL/6 mice. Groups of 12 Ncr1
gfp/gfp , or IFN-g-deficient mice were injected s.c. with 5 3 10 5 of the various MCA-induced tumor cells, and tumor size was measured every 2-3 d after injection using a micrometer.
NK cell depletion
Mice were injected i.v with 200 mg anti-NK1.1 Ab (PK136) in 200 ml sterile PBS. Ab was injected into the tail vein every 7 d during the experiment. Sterile PBS was injected as a control. Depletion was verified every 3 d after injection. 
In vitro cytotoxicity assays
In vivo lung clearance assay
For the in vivo clearance assay, we used a published fluorescence labeling method with a modification to avoid possible influence of intrinsic GFP present in the Ncr1 gfp/gfp mice. Target cells were labeled with Vybrant Dil cell labeling solution (Molecular Probes, Carlsbad, CA), and control HeLa cells were labeled with Vybrant DiD. A total of 2 3 10 6 cells of each of the cell type were mixed in 400 ml PBS and injected into the tail vein of C57BL/6 Ncr1 +/+ or Ncr1 gfp/gfp mice. Lungs were explanted 3 h later. Single-cell suspensions were obtained by using a cell strainer, and fluorescence was analyzed by flow cytometry. The ratio of the tested MCA-induced cell lines target cells to the internal control HeLa cells was calculated.
CD107a assays
Mice were injected i.p with 200 mg poly(I):poly(C), and spleens were removed 18 h later. NK cells were isolated from splenocytes using the mouse NK isolation kit (Miltenyi Biotec, Auburn, CA) and an autoMACS instrument according to the manufacturer's instruction. NK cells ( 
Cytokine secretion assay
Mice were injected i.p. with 200 mg poly(I):poly(C), and spleens were removed 18 h later, splenocytes were extracted, and NK cells were isolated as described above. NK cells (50,000) were coincubated with the indicated target cells at a ratio of 1:1 for 48 h at 37˚C and 5% CO 2 . Supernatants were collected and IFN-g levels were determined using a commercially available ELISA assay (BD Pharmingen).
Results
NCR1 plays no significant role in the development of MCA-induced fibrosarcomas
It was previously demonstrated that NCR1 is involved in the in vivo killing of some tumor cell lines (7, 17, 18) . To address the role played by NCR1 in carcinogen-induced tumors, we used the MCA-induced fibrocarcinoma model. NCR1 KO-Ncr1 gfp/gfp and wild-type (WT)-Ncr1 +/+ littermates were injected with MCA, and fibrosarcomas arose at the site of injection after a long latency period. Fig. 1 demonstrates the timeline of tumor progression in KO and WT mice. In MCA-injected mice (50 mg/mouse), tumors began to appear in the Ncr1 gfp/gfp mice 78 d postinjection, whereas in the Ncr1 +/+ mice tumors appeared ∼20 d later (Fig. 1A) . When lower doses of MCA were injected (25 mg/mouse), tumors started to appear in the Ncr1 gfp/gfp mice at ∼88 d postinjection, whereas in the Ncr1 +/+ mice, tumors were observed ∼10 d later (Fig. 1B) . Finally, early initial tumor growth was also observed in the Ncr1 gfp/gfp injected with 5 mg/mouse MCA (Fig. 1C) . The differences observed between the Ncr1 gfp/gfp and the Ncr1 +/+ were noted only in one to two mice, and in most cases, there were no significant differences in the tumor growth rates between the Ncr1 gfp/gfp and Ncr1 +/+ mice ( Fig.  1) . Thus, we concluded that NCR1 plays no significant role in preventing the development of the MCA-induced fibrosarcomas.
NKp46-mediated immunoediting
To further investigate the role played by NCR1 in MCA-induced tumor cell recognition, we generated cell lines from the primary tumors of both Ncr1 gfp/gfp and Ncr1 +/+ genotypes. Cell lines with a WT or KO suffix were originated from Ncr1 +/+ or Ncr1 gfp/gfp mice, respectively. Because the NCR1 ligands are unknown, we studied whether NCR1 recognizes ligands on the MCA-induced cell lines by using NCR1-Ig and NKp46-Ig fusion proteins. For this purpose, the extracellular portion of each receptor was fused to the Fc of human IgG1, as described previously (13) . As can be seen in Fig. 2A , all cell lines were recognized by NCR1-Ig fusion protein. Remarkably, we noticed that all cell lines that originated in the WT mice expressed low levels of NCR1 ligands, whereas cell lines that originated in NCR1-deficient mice expressed, in general, higher levels of NCR1 ligands ( Fig. 2A ). Several KO cell lines such as 19KO, 70KO, 79KO, and 99KO expressed lower levels of NCR1 ligands compared with the other KO cell lines. However, on average, the levels of the NCR1 ligands were higher in the Ncr1 gfp/gfp mice as compared with their WT littermates ( Fig.  2A) . Furthermore, all cell lines expressed low levels of NKG2D ligands, irrespective of whether they were generated in the WT or in the Ncr1 gfp/gfp mice ( Fig. 2B and data not shown). To further investigate whether indeed in the presence of NCR1 the emerging tumors express less NCR1 ligands, we used an additional assay using reporter cell lines. BW cells are mouse thymoma tumor cells that had been transfected with constructs encoding a chimeric
In this system, triggering the chimeric protein by its ligand will lead to the secretion of IL-2 (thus, the unknown NCR1 ligands, if present, should induce IL-2 production). Because we observed that the human NKp46-Ig recognizes the MCA tumor ligands similarly as NCR1-Ig (examples are shown in Fig. 3A and data not shown), we used the BW cells expressing the human NKp46 protein fused to z-chain to address the functional relevance of the NCR1 ligands. Importantly, and in agreement with the NCR1-Ig binding results (Fig. 2) , only the tumors that originated in the NCR1-deficient mice were able to stimulate IL-2 production and secretion to a level similar to that observed after cross-linking the NKp46-z chimeric receptor by a mAb (Fig. 3B) . In contrast, all tumors that were isolated from WT mice failed to induce IL-2 secretion (Fig. 3B ). These observations imply on the existence of NCR1-mediaed tumor immunoediting process. As expected, because of tumor heterogeneity, not all tumors that originated in the Ncr1 gfp/gfp mice induced NKp46-mediated IL-2 secretion. Importantly, a direct correlation was observed between the expression of the NCR1 ligands detected by the NCR1-Ig fusion protein ( Fig. 2A ) and the stimulation of the IL-2 production. The KO cell lines, which demonstrated low levels of NCR1 ligands expression (19KO, 70KO, 79KO, and 99KO; Fig.  2A ), did not stimulate IL-2 secretion whereas others, which express high levels of the NCR1 ligands, did (Fig. 3B) . Thus, in the presence of NCR1, the developing tumors undergo an immunoediting process aiming at reducing NKp46 ligands expression.
Increased immunogenicity of the Ncr1 gfp/gfp -derived cell lines
Becausethe NCR1ligands are downregulatedwhentumorsgrowinthe WT mice facing NCR1 pressure, we assumed that these ligands might influence tumor growth. We therefore injected MCA-induced tumor cell lines that express either high or low levels of the NCR1 ligands into Ncr1 gfp/gfp and Ncr1 +/+ mice. Tumor sizes were measured for a period of 3 wk until the tumors had grown too big and the mice had to be sacrificed because of ethical reasons.
In accordance with our prediction, the tumors that originated in the absence of NCR1 (such as 60KO, 20KO, and 82KO) and expressed the putative cellular NCR1 ligands, grew faster and reached a bigger mass in Ncr1 gfp/gfp mice as compared with the Ncr1 +/+ mice (Fig. 4A) . In contrast, tumors that originated in the Ncr1 +/+ mice facing the NCR1-dependent immunoediting process, such as cell lines 2WT, 3WT, and 40WT, demonstrated similar growth kinetics in WT and in the NCR1-deficient mice (Fig. 4A) . Importantly, a direct correlation was observed between the NCR1-Ig staining (Fig. 2) , the BW reporter assays (Fig. 3) and the in vivo growth of the different tumors. No differences in tumor growth rates were observed when low levels of NCR1 ligands were present (even with the 19KO, which expresses low levels of NCR1 ligands), whereas differences were noticed when tumors expressed high levels of the unknown ligands (Fig. 4A) . The growth rate differences were NCR1 dependent and NK cell dependent as when NK cells were depleted by injection of anti-NK1.1 Abs, the tumor growth rates of the WT and Ncr1 gfp/gfp mice were similar (Fig. 4B) .
The killing of all MCA-induced tumors is NKG2D but not NCR1 dependent
Next we sought to determine the mechanism responsible for the differences in the tumor growth. We first performed in vitro killing assays using splenocytes isolated from either Ncr1 gfp/gfp or Ncr1 +/+ mice and incubated them with the MCA-induced tumor cell lines. Ncr1 +/+ and Ncr1 gfp/gfp mice were preactivated by poly(I):poly(C) before performing the experiments, because in the absence of such stimulation, the basal killing of target cells by NK cells was minimal (data not shown). As can be seen in Fig. 5A , all of the MCA-induced tumor cells were killed by activated NK cells, but no differences were observed in the percentages of specific killing among the various NK cells derived either from Ncr1 gfp/gfp , from Ncr1 +/+ , or from the Ncr1 gfp/+ mice (data not shown). We next assumed that it might be that the poly(I):poly(C) activation of NK cells, which results in increased killing, abrogate the differences that exists between the Ncr1 gfp/gfp and the Ncr1 +/+ mice. We therefore used the in vivo lung clearance assay in which NK cells are not manipulated. Fluorescence-labeled tumors cells were injected into the tail vein of the various mice. Because the injection of cells might vary between different mice and as we aimed to compare between the ability of the Ncr1 gfp/gfp and Ncr1 +/+ mice to kill tumor cells in vivo, each injection was controlled by reference cells such as HeLa cells. As can be seen in Fig. 5B , no differences were observed between the Ncr1 gfp/gfp and Ncr1 +/+ mice, even in the in vivo lung clearance killing assays. Moreover, the cell line 2WT, which expresses low levels of the NCR1 ligands, was killed more efficiently in vivo, as compared with line 82KO (Fig. 5B) , further indicating that NCR1 plays no significant role in the killing of the fibrosarcoma tumors. The PD1.6 tumor cell line, which is killed in vitro and in vivo by NK cells in an NCR1-dependent manner (17) , was used as a positive control and, indeed, it exhibited increased killing by the Ncr1 +/+ NK cells. Thus, we concluded that NCR1 plays no role in the MCA tumor killing.
It was previously shown that NKG2D is involved in the killing of MCA-induced tumors (22) . To test the role of NKG2D in the presence and in the absence of NCR1, we stained the NK cells from Ncr1 gfp/gfp and heterozygous-Ncr1 gfp/+ mice for CD107a (LAMP-1, a marker for cytoplasmic granules release), after incubating the NK cells with the various MCA-induced tumors cell lines. We used the Ncr1 gfp/gfp and the Ncr1 +/gfp mice, because in these mice, NK cells can be visualized specifically and accurately, as a GFP reporter gene was introduced into the Ncr1 locus (7). The Ncr1 +/gfp mice are normal and behave similarly to the Ncr1 +/+ mice (7, 24, 25) . As above, no significant difference in the surface expression of CD107a was observed between the NK cells derived either from the Ncr1 +/gfp or from the Ncr1 gfp/gfp mice (Fig. 5C) . Importantly, the killing of all MCA-induced cell lines, irrespective of whether they were obtained from the Ncr1 gfp/gfp or Ncr1 +/+ mice, was NKG2D dependent as it was blocked by an anti-NKG2D mAb (Fig. 5C ).
Thus, NKG2D and not NCR1 is involved in the killing of the MCAinduced tumor by NK cells.
NCR1 ligands trigger IFN-g secretion
Activation of NK cells could result in direct cytotoxicity and/or in cytokine secretion, mainly IFN-g. Because we observed that NCR1 plays no significant role in the direct killing of the MCA- induced tumors (Fig. 5) , our next goal was to determine whether the NCR1 ligands are involved in IFN-g secretion by NK cells. NK cells were extracted from poly(I):poly(C)-activated splenocytes of both Ncr1 +/gfp and Ncr1 gfp/gfp mice and were incubated with MCA-induced tumor cell lines or control tumor cells lines. Supernatants were collected 48 h later and tested for the presence of IFN-g by ELISA. Significantly higher levels of IFN-g were observed when NK cells derived from the Ncr1 +/gfp mice were incubated with target cells that originated in the Ncr1 gfp/gfp mice (Fig. 6 ). IFN-g secretion was not enhanced above the background level when NK cells were incubated with tumor cell lines that originated in the Ncr1 +/+ mice or with cell lines that originated in the Ncr1 gfp/gfp mice but express low levels of the NCR1 ligands (Fig. 6 ). When HeLa cells, which do not express the murine NKp46 ligands, were incubated with the NK cells no IFN-g secretion was observed.
The Ncr1 gfp/gfp NK cells were not defective in their IFN-g production, because equal amounts of IFN-g were detected when YAC-1 cells were incubated with NK cells derived from both genotypes. Because IFN-g secretion was not detected when NCR1 ligands were absent (Fig. 6) , we concluded that the MCA-induced tumors are killed mainly in an NKG2D-dependent manner (Fig. 5) , whereas the production of cytokines is mainly NCR1 dependent.
To demonstrate in vivo that the unknown NCR1 ligands are involved in the secretion of IFN-g by NK cells, we injected the various MCA-induced tumor cell lines into IFN-g-deficient mice (B6.129S7-Ifng tm1Ts /J). As predicted, in the IFN-g-deficient mice, the tumor sizes were similar between the Ncr1 gfp/gfp and the IFN-gdeficient mice in all MCA-induced cell lines (Fig. 7) . As above, reduced tumor growth rates were observed in the WT mice when MCA-induced tumors expressing high levels of NCR1 ligands were used (Fig. 7) .
Taken together, our results demonstrate a novel NCR1-dependent tumor immunoediting process of MCA-induced tumors, which probably evolved to diminished IFN-g secretion.
Discussion
The MCA-induced fibrosarcoma model has been used to establish principles of tumor immunosurveillance and immunoediting (19, 26, 27) . It was previously reported that MCA-induced tumors were more frequent in mice treated for a long period of time with blocking NKG2D Abs (22) . In contrast, another report failed to observe an increased incidence of MCA-induced sarcomas in NKG2D-deficient mice (19) . The reasons for these discrepancies are not completely understood; however, because NKG2D is not expressed exclusively by NK cells, it is still unclear whether the absence of an NK specific killer receptor will affect MCA-induced tumor growth.
By using the MCA model in the Ncr1 gfp/gfp gene-targeted mice, we were able to address two important issues. The first is whether NCR1 is crucial for immune surveillance of MCA-induced fibrosarcomas in vivo and the second is whether there is a selective pressure that will favor the downregulation of the unknown NCR1 ligands (i.e., immunoediting). In this paper, we report that although NCR1 does not play a significant role in preventing the +/+ , and IFN-g-deficient mice (500,000 cells/mouse). Tumor size was measured during a 3-wk period. Shown is one representative experiment of three performed.
formation of MCA-induced fibrosarcomas, the developing tumors, facing the NCR1 pressure, downregulate its unknown ligands.
Many different functions are assigned to NK cells (28) , and it was even demonstrated that NK cells possess some adoptive immunity features (29) (30) (31) . In addition to their cytolytic ability, a wellestablished function of NK cells is cytokine secretion (32) . IFN-g is a prototypic NK cell cytokine that was shown to be essential for the rejection of transplanted tumor cells and for the decrease in MCAinduced tumor growth (33) . Importantly, we show that in the MCAmodel, IFN-g secretion by NK cells is NCR1 dependent, because cell lines that originated in Ncr1 +/+ mice and express low levels of the NCR1 ligands could not trigger the IFN-g secretion by NK cells. As expected, because of tumor heterogeneity, not all cell lines that originated in the Ncr1 gfp/gfp expressed high levels of the NCR1 ligands. In general, however, we observed higher levels of NCR1 ligands in tumors developed in vivo in the absence of NCR1, and in all cases, a direct correlation was observed between the expression of the NCR1 ligands (as detected by NCR1-Ig staining or BW reporter assays), IFN-g secretion, and the in vivo growth of tumors. Thus, in the presence of NCR1, developing tumor undergo an immunoediting process to reduce the NCR1 ligands expression, probably to affect IFN-g secreted by NK cells.
The unknown NCR1 ligands seem to have a dual role, either inducing cytokine secretion (as shown in this paper for the MCAinduced tumors) or promoting cytolytic activity by NK cells (as shown for some lymphomas [17] ). Several reasons could account for this observation. It is possible that various ligands exist for NCR1, some of which activate cytokine secretion, some are involved in NK cytotoxicity, and others might promote both activities. Alternatively, it is possible that the same ligands are involved in NK cytotoxicity and cytokine production, and the outcome of the NK cell response and the magnitude of the effect are determined by additional factors, which might be cell specific. It has indeed been demonstrated that the activation of NKp46 could not induce cytotoxicity of freshly isolated NK cells but rather requires the ligation of additional receptors to exert the NK activity. However, in activated NK cells, the engagement of NKp46 alone triggers cytotoxicity (34) . The only ligands identified so far for NKp46/NCR1 are various viral hemagglutinins (HAs) (7, 13) . It was shown that NK cells kill virusinfected melanoma cells such as 1106mel through the interactions between the NKp46 receptor and the viral HA (13) . In contrast, when dendritic cells where infected with the influenza virus, the interaction between NKp46 and HA led to IFN-g secretion and not to cytotoxicity (35) . Finally, we recently demonstrated that the interactions between NKp46 and the HA protein H1 could directly lead to cytotoxicity, whereas when NKp46 interacts with the H5 HA, additional receptors were needed to enhance the killing (36) . Thus, even when NKp46 is triggered by the same HA ligand, the functional outcome of such activation might be different.
We show in this paper that in the MCA-induced model, the NKp46 ligands are involved in IFN-g secretion. We and other showed that NKp46 is important for melanoma and lymphoma eradication (17, 18) , and recently, we demonstrated that the NKp46 ligands are also involved in type 1 diabetes development (37) . Clearly, the identification of the unknown NKp46 ligand is of special importance. We think that the MCA-induced tumor cell lines generated in this study, which express high and low levels of the unknown NKp46 ligands, are not only a good example of tumor immunoediting but also that these cell lines might also be a valuable tool for the NKp46 ligand identification.
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